FILING ANALYSIS · THURSDAY, OCTOBER 29
LIGAND PHARMACEUTICALS INC LGND — 8-K: Results of Operations and Financial Condition
positive
Ligand Pharmaceuticals reported a 51% year-over-year increase in royalty revenue to $70.3 million and raised its full-year 2026 adjusted diluted EPS guidance to $9.50 to $9.75, driven by strong performance from its key royalty assets and the XOMA portfolio.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →